Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (1878)	9/7/2007 4:24:11 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

Steve, DVAX Is up for the 3rd day on a roll in spite of the general market. bigcharts.marketwatch.com It seems to have good support at the $4 level & its nearest resistance is at the July 5 H of $5.19 before it can try to test its April 9 H at $5.81 It seems to be helped by announcement of the patent covering the its TLR9 agonists & the presentation by Dino, scheduled at Bear Stearns Annual Healthcare Conference in N.Y. on Monday. It has 4 consecutive Qs of triple digit improvement on revenues & the loss was cut some on the last (2nd) Q. Another one with 3 days of up-move in spite of the general market correction, is INGN, which today was able to close above the resistance of the double top (May 30-June 1)at the $4.75 level. It also has support at the $4 level & its resistance is now at the May 8 H of $5 before it can test the more important resistance from the April 25 H at $5.44 & the April 18 spike H at $6.35 <g> bigcharts.marketwatch.com But as I mentioned to Jason on comments on GILD, I still am on a "wait & see mode" on account of the general market, since I think is better not to get too enthusiastic on the buy while the general market remains unstable. Message 23856970 Bernard